# Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

> **NCT05707325** · EARLY_PHASE1 · RECRUITING · sponsor: **Westlake Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Cancer
- Solid Tumor
- Hematologic Malignancy

## Interventions

- **DRUG:** engineered red blood cell

## Key facts

- **NCT ID:** NCT05707325
- **Lead sponsor:** Westlake Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-16
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05707325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05707325, "Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05707325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*